ALLG LS27: A genomic study of lymphoma in patients with suspected inborn errors of immunity.

This prospective observational study will enroll individuals with lymphoma and suspected inborn errors of immunity (IEI). A blood and saliva sample will be collected at a visit after they have been enrolled from in an initial cohort of 20 patients. Whole exome sequencing will be used to assess these samples. Phase 1 of analysis will involve focused analysis of 99 genes recurrently implicated in immunodeficiency which draws upon national and international recommendations such as IEI Committee guidelines and Panel App. Phase 2 of analysis will involve analysis of all genes in exome sequencing to discover novel genes potentially implicated in IEI and lymphoma. Simultaneously clinicopathologic data, testing for chronic viral infections (such as EBV), treatment toxicity data, outcome data including response and survival. Diagnostic tissue samples and peripheral blood will be collected for further testing which includes Next-Generation Sequencing profiling of tumor and immune cell repertoire, assessment of the tumor microenvironment as part of additional correlative studies. There will be no mandated assessments beyond those required for standard diagnosis, treatment, and follow-up of lymphoma patients at the participating centres. All clinical data and samples will be collected according to routine care with focus on treatment toxicity. The schedule of assessments will therefore vary depending on the specific lymphoma subtype and treatment.